Polyplus-transfection SA, a privately-held company developing innovative technologies for molecular and cellular biology, and Blue Sky BioServices, a contract research organization (CRO) providing ...

Polyplus-transfection has announced that it is setting up a group called the "Polyplus in vivo Consortium". This group will be developed on a user group model and bring together research scientists ...

Strasbourg-based Polyplus-transfection started construction of Vectura, a new 4,000-square-meter facility which is being built to enable the company to continue to tap into the exponential growth in ...

Polyplus-transfection(R) SA, the leading biotechnology company that supports gene and cell therapy by supplying innovative transfection solutions, today announces the availability of the first ...

Warburg Pincus has made an investment in Polyplus, a developer of technology used in gene and cell therapy. Warburg’s investment in Polyplus puts the latter at a valuation of more than 500 million ...

Neurons, neural stem cells, and other slowly dividing cells are notoriously difficult to transfect. With CRISPR-based gene editing gaining momentum, transfection is an essential technique in the ...

Sartorius announced the 2.4 billion euro acquisition of Polyplus. Polyplus is producing transfection reagents and generates 100 million euros in revenues. The acquisition appears to be very expensive ...

PEI transfection reagents are designed to enable protein production in the medium-to-large scale ranges. ExcellGene, a provider of solutions for protein manufacturing and process development based on ...

Warburg Pincus agreed to sell Polyplus for €2.4 billion earlier than expected, with the company in high demand despite a challenging exit market – one that requires more “bespoke” approaches, managing ...

Sartorius Stedim Biotech agreed to buy Polyplus, a maker of components for cell and gene therapies, for about €2.4 billion ($2.6 billion) from a group of private investors. The deal would bolster ...